➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Merck
Johnson and Johnson
McKinsey

Last Updated: October 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRABECTEDIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for trabectedin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002904 ↗ Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 1 1996-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid tumors.
NCT00003939 ↗ Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 1969-12-31 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma.
NCT00005625 ↗ Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma Completed National Cancer Institute (NCI) Phase 2 1999-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00005625 ↗ Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma Completed Memorial Sloan Kettering Cancer Center Phase 2 1999-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00017030 ↗ Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma Completed National Cancer Institute (NCI) Phase 2 2001-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
NCT00017030 ↗ Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma Completed Memorial Sloan Kettering Cancer Center Phase 2 2001-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for trabectedin

Condition Name

Condition Name for trabectedin
Intervention Trials
Sarcoma 12
Soft Tissue Sarcoma 10
Leiomyosarcoma 7
Ovarian Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for trabectedin
Intervention Trials
Sarcoma 39
Ovarian Neoplasms 15
Liposarcoma 13
Leiomyosarcoma 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for trabectedin

Trials by Country

Trials by Country for trabectedin
Location Trials
United States 251
Italy 127
Spain 26
Germany 20
France 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for trabectedin
Location Trials
New York 14
California 14
Massachusetts 13
Pennsylvania 12
Washington 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for trabectedin

Clinical Trial Phase

Clinical Trial Phase for trabectedin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 14
Phase 2/Phase 3 1
[disabled in preview] 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for trabectedin
Clinical Trial Phase Trials
Recruiting 29
Completed 28
Not yet recruiting 18
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for trabectedin

Sponsor Name

Sponsor Name for trabectedin
Sponsor Trials
PharmaMar 35
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 12
National Cancer Institute (NCI) 11
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for trabectedin
Sponsor Trials
Other 85
Industry 75
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.